A Phase II/III Multicenter Study Evaluating
the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial), NCT03178552
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic NSCLC determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA) assays.
MORE DETAILS ON THIS LUNG CANCER TRIAL
17030 / NCT03178552 / BO29554 / Open 11-20-2017 / Cohort B Closed 7-20-2018
TRIAL AVAILABLE AT THESE LOCATIONS
All RMCC Locations